Search

Your search keyword '"Caponigro F"' showing total 280 results

Search Constraints

Start Over You searched for: Author "Caponigro F" Remove constraint Author: "Caponigro F"
280 results on '"Caponigro F"'

Search Results

1. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial †

2. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

3. 862MO Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer

5. Percorso diagnostico, terapeutico e assistenziale per i tumori di testa e collo – Aggiornamento 2020 AIOCC

7. Management of recurrent nasopharyngeal carcinoma: current perspectives

17. A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck

21. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications

22. First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial

24. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

25. 1140P - A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck

26. OC-005: Afatinib versus methotrexate in recurrent/metastatic HNSCC after platinum therapy: LUX-head and neck

31. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

34. Afatinib Versus Methotrexate (Mtx) As Second-Line Treatment for Patients with Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Who Progressed After Platinum-Based Therapy: Primary Efficacy Results of Lux-Head & Neck 1, a Phase III Trial

35. Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?

38. Phase II study of E7070 in patients with metastatic melanoma.

39. 583 Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Head and Neck Cancer. Preliminary Results of a Phase I/II Study

41. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

42. Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer

43. Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.

44. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

49. Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

Catalog

Books, media, physical & digital resources